Millennium Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-58,626
| Closed | -$3.44M | – | 6867 |
|
|
2023
Q4 | $3.44M | Buy |
58,626
+24,246
| +71% | +$1.36M | ﹤0.01% | 3120 |
|
|
2023
Q3 | $1.5M | Sell |
34,380
-470,929
| -93% | -$16.8M | ﹤0.01% | 3841 |
|
|
2023
Q2 | $18.3M | Buy |
505,309
+486,275
| +2,555% | +$20M | 0.01% | 1469 |
|
|
2023
Q1 | $708K | Sell |
19,034
-129,766
| -87% | -$5.84M | ﹤0.01% | 4377 |
|
|
2022
Q4 | $6.74M | Buy |
148,800
+137,588
| +1,227% | +$8.9M | ﹤0.01% | 2536 |
|
|
2022
Q3 | $783K | Sell |
11,212
-199,228
| -95% | -$14.7M | ﹤0.01% | 4550 |
|
|
2022
Q2 | $14.1M | Buy |
210,440
+90,068
| +75% | +$5.73M | 0.01% | 1642 |
|
|
2022
Q1 | $9.9M | Buy |
120,372
+42,444
| +54% | +$4.34M | 0.01% | 2186 |
|
|
2021
Q4 | $11.4M | Buy |
77,928
+26,487
| +51% | +$4.11M | 0.01% | 2000 |
|
|
2021
Q3 | $9.1M | Sell |
51,441
-440,796
| -90% | -$70.9M | 0.01% | 2185 |
|
|
2021
Q2 | $79.5M | Buy |
492,237
+369,794
| +302% | +$59.4M | 0.05% | 399 |
|
|
2021
Q1 | $21M | Buy |
122,443
+91,491
| +296% | +$18.1M | 0.02% | 1057 |
|
|
2020
Q4 | $6.8M | Buy |
30,952
+11,764
| +61% | +$2.54M | ﹤0.01% | 2152 |
|
|
2020
Q3 | $3.19K | Buy |
+19,188
| New | +$2.63M | ﹤0.01% | 2221 |
|
|
2020
Q2 | – | Sell |
-40,863
| Closed | -$3.14M | – | 4723 |
|
|
2020
Q1 | $3.14M | Buy |
40,863
+34,121
| +506% | +$3.06M | 0.01% | 1697 |
|
|
2019
Q4 | $869K | Sell |
6,742
-4,767
| -41% | -$460K | ﹤0.01% | 3070 |
|
|
2019
Q3 | $896K | Sell |
11,509
-147,669
| -93% | -$13.9M | ﹤0.01% | 2912 |
|
|
2019
Q2 | $16.4M | Buy |
+159,178
| New | +$12.4M | 0.02% | 911 |
|
|
2018
Q4 | – | Sell |
-42,599
| Closed | -$2.01M | – | 4291 |
|
|
2018
Q3 | $2.01M | Buy |
+42,599
| New | +$2.37M | ﹤0.01% | 2435 |
|
|
2018
Q2 | – | Sell |
-381,924
| Closed | -$14.4M | – | 4282 |
|
|
2018
Q1 | $11.7M | Buy |
+381,924
| New | +$10.6M | 0.02% | 1235 |
|
|
2017
Q4 | – | Sell |
-445,709
| Closed | -$5.21M | – | 4161 |
|
|
2017
Q3 | $5.21M | Buy |
445,709
+227,719
| +104% | +$1.32M | 0.01% | 1650 |
|
|
2017
Q2 | $796K | Buy |
217,990
+100,326
| +85% | +$384K | ﹤0.01% | 2572 |
|
|
2017
Q1 | $612K | Sell |
117,664
-43,641
| -27% | -$239K | ﹤0.01% | 2704 |
|
|
2016
Q4 | $766K | Buy |
161,305
+85,004
| +111% | +$462K | ﹤0.01% | 2403 |
|
|
2016
Q3 | $504K | Sell |
76,301
-214,797
| -74% | -$1.14M | ﹤0.01% | 2601 |
|
|
2016
Q2 | $1.59M | Buy |
291,098
+196,422
| +207% | +$3.13M | ﹤0.01% | 1909 |
|
|
2016
Q1 | $2.03M | Buy |
94,676
+70,368
| +289% | +$1.57M | 0.01% | 1764 |
|
|
2015
Q4 | $768K | Buy |
24,308
+5,836
| +32% | +$206K | ﹤0.01% | 2430 |
|
|
2015
Q3 | $636K | Buy |
+18,472
| New | +$558K | ﹤0.01% | 2537 |
|
Other funds holding MRTX
Millennium Management's MRTX Position: Q1 2024 in Review
Millennium Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 58,626 shares — an estimated $3.44M sold.
Millennium Management first reported a position in MRTX in Q3 2015 and held it in 29 quarters. The position peaked at $79.5M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Millennium Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Millennium Management sold 58,626 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.44M.
- Millennium Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 29 quarters.
- Millennium Management's Mirati Therapeutics, Inc. Common Stock position peaked at $79.5M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.